Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.
The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer. AU-011 consists of a VLP conjugated to a photoactivatable dye, which binds preferentially to tumor cells in the eye. Once bound, the treatment is activated by a noninvasive near-infrared laser, triggering a localized photochemical reaction that selectively kills cancer cells. Early‐stage clinical trials have demonstrated encouraging safety and tumor control signals, supporting ongoing pivotal development.
In addition to its ophthalmic program, Aura Biosciences is advancing research in head and neck cancers and other solid tumor indications. The company is collaborating with leading academic centers and research institutions to explore combination regimens and to expand the therapeutic potential of its VLP platform. Aura’s development strategy includes both monotherapy and combination approaches, with plans to initiate additional clinical studies in the coming years.
Founded in 2015 and headquartered in Cambridge, Massachusetts, Aura Biosciences has built a leadership team with extensive experience in oncology drug development and photodynamic therapy. The company maintains operations in North America and Europe, and it listed its common shares on the Nasdaq Global Market under the ticker symbol AURA. With a growing pipeline and a differentiated technology platform, Aura is positioned to address significant unmet needs in the treatment of solid tumors through targeted, light-activated therapeutics.
AI Generated. May Contain Errors.
